Likewise, our in vitro studies on human hepatoma cell lines and 3D spheroid cultures indicate that IL-1β released by activated macrophages may contribute to tumor growth and impact the antitumoral activity of sorafenib. Here, IL1B is linked to hepatocellular carcinoma.